BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fu T, Guzzetta AA, Jeschke J, Vatapalli R, Dave P, Hooker CM, Morgan R, Iacobuzio-Donahue CA, Liu B, Ahuja N. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma. Int J Cancer. 2013;132:2502-2509. [PMID: 23065691 DOI: 10.1002/ijc.27910] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Patankar M, Eskelinen S, Tuomisto A, Mäkinen MJ, Karttunen TJ. KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells. Mol Med Rep 2019;20:4634-44. [PMID: 31545494 DOI: 10.3892/mmr.2019.10693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande SV, Banerjee S. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. Curr Genomics 2018;19:444-63. [PMID: 30258276 DOI: 10.2174/1389202919666180221160753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
3 Zhao P, Chen H, Wen D, Mou S, Zhang F, Zheng S. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Commun (Lond) 2018;38:54. [PMID: 30139386 DOI: 10.1186/s40880-018-0323-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
4 Matsuzaki J, Suzuki H, Shimoda M, Mori H, Fukuhara S, Miyoshi S, Masaoka T, Iwao Y, Kanai Y, Kanai T. Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma. United European Gastroenterol J 2019;7:250-60. [PMID: 31080610 DOI: 10.1177/2050640618817689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, Thirot-Bidault A, Sobhani I, Malka D, Lecomte T, Locher C, Bonnetain F, Laurent-Puig P. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 2013;109:3057-66. [PMID: 24196786 DOI: 10.1038/bjc.2013.677] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
6 Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan W, Baylin SB, Wolfgang CL, Ahuja N. Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. PLoS One 2016;11:e0162929. [PMID: 27643594 DOI: 10.1371/journal.pone.0162929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Chandrasegaram MD, Gill AJ, Samra J, Price T, Chen J, Fawcett J, Merrett ND. Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. World J Gastrointest Oncol 2017; 9(10): 407-415 [PMID: 29085567 DOI: 10.4251/wjgo.v9.i10.407] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
8 Watari J, Mitani S, Ito C, Tozawa K, Tomita T, Oshima T, Fukui H, Kadowaki S, Natsume S, Senda Y, Tajika M, Hara K, Yatabe Y, Shimizu Y, Muro K, Morimoto T, Hirota S, Das KM, Miwa H. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Sci Rep 2019;9:10526. [PMID: 31324814 DOI: 10.1038/s41598-019-46167-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Jun S, Kim M, Jin Gu M, Kyung Bae Y, Chang H, Sun Jung E, Jang K, Kim J, Yu E, Woon Eom D, Hong S. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. Mod Pathol 2016;29:402-15. [DOI: 10.1038/modpathol.2016.40] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
10 Chandrasegaram MD, Chen JW, Price TJ, Zalcberg J, Sjoquist K, Merrett ND. Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas. 2016;45:32-39. [PMID: 26348463 DOI: 10.1097/mpa.0000000000000385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]